toxicology-conference-2017-scientifictracks

11 / 20

Page 35
Notes:
allied
academies
J Clin Exp Tox 2017 Volume 1 | Issue 2
Toxicology and Pharmacology
November 01-02, 2017 | Toronto, Canada
International Conference on
The CardioExcyte 96 is a hybrid screening instrument that
combines impedance with MEA-like extracellular field
potential (EFP) recordings. Changes in the impedance signal
indicate effects on cell contractility and overall shape, whereas
the field potential parameters provide information about the
electrophysiological activity of the beating network of cells. The
ongoing Comprehensive in-vitro Proarrhythmia Assay (CiPA) is
a FDA directed initiative to improve guidelines and standardize
assays for determining the proarrhythmic risk of potential drug
candidates. In agreement with the CiPA initiative, standard
protocols and SOPs were created for the CardioExcyte96, as well
as automated data analysis on required endpoints. Workshop
presents the workflow of utilizing the CardioExcyte96 for the
assessment of acute/chronic cardiotoxicity in cultured iPSC
cardiomyocytes. Cytotoxic responses of cell monolayers involve
metabolic or biochemical changes that affect themorphology of
the cells, or reduce their overall viability. In that regard, effects
of reference compounds tested for long-term cytotoxicity in
hepatocyte-like cells will be presented.
Speaker Biography
Corina T Bot obtained her PhD in Applied Physics from New Jersey Institute of
Technology in 2010. Next, she worked for two years as a Post-doctoral Associate in
Cardiology, at Cornell University, Weill Cornell Medical College. In her current position
as a Senior Scientist at Nanion Technologies, she provides technical and scientific
support for cell-based electrophysiology and toxicology assays, and automated patch
clamp screening. Together with her colleagues at Nanion, she is participating in the
FDA-directed Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative, which
aims to replace the preclinical hERG current assay required under the ICH S7B safety
pharmacology guidelines and clinical TQT study.
e:
Corina T Bot
Nanion Technologies, Germany
Impedance and extracellular field potential for cardiac safety assays: A combined
approach for non-invasive screening of iPS cells